Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 5Recurrence 3Glioma 3Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Neoplasms 1Lymphoma, Follicular 1Lung Neoplasms 1Gliosarcoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 26Magnetic Resonance Spectroscopy 19Etoposide 12Cyclophosphamide 12Radiotherapy 11Bevacizumab 10Filgrastim 9Biopsy 8Carboplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Cisplatin 6Carmustine 6Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4olaparib 3etoposide phosphate 3Vincristine 3Surveys and Questionnaires 3Lapatinib 3Gadolinium DTPA 3Azacitidine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × cemiplimab × CNS × Clear all
NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
120 enrolled
CNS

Ependymoma, Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡